我武生物
(300357)
| 流通市值：106.40亿 | | | 总市值：115.08亿 |
| 流通股本：4.84亿 | | | 总股本：5.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 228,471,779.62 | 925,394,524.96 | 730,238,304.07 | 429,257,047.81 |
| 营业收入 | 228,471,779.62 | 925,394,524.96 | 730,238,304.07 | 429,257,047.81 |
| 二、营业总成本 | 144,752,871.67 | 578,606,136.89 | 427,571,052.51 | 265,408,191.17 |
| 营业成本 | 11,970,272.03 | 44,809,559.78 | 34,634,787.12 | 21,687,521.14 |
| 税金及附加 | 978,789.53 | 9,729,074.88 | 4,657,424.06 | 3,500,831.66 |
| 销售费用 | 92,234,264.06 | 361,427,171.25 | 270,793,761.25 | 163,437,646.75 |
| 管理费用 | 16,858,018.92 | 73,221,145.2 | 52,758,384.8 | 33,647,865.87 |
| 研发费用 | 29,641,964.59 | 119,882,840.88 | 87,862,042.99 | 59,253,401.99 |
| 财务费用 | -6,930,437.46 | -30,463,655.1 | -23,135,347.71 | -16,119,076.24 |
| 其中:利息费用 | 219,729.74 | 1,064,296.51 | 899,572.95 | 619,422.91 |
| 其中:利息收入 | 7,172,279.88 | 31,767,052.92 | 24,233,008.41 | 16,904,748.52 |
| 加:公允价值变动收益 | 395,090.71 | 2,429,584.92 | -763,407.78 | 30,176.23 |
| 加:投资收益 | 151,575.33 | 4,040,186.3 | 6,482,593.58 | -53,108.98 |
| 资产处置收益 | 630,073.33 | 568,926.85 | 568,926.85 | 353,473.3 |
| 信用减值损失(新) | -979,914.68 | -958,291.22 | -4,921,945.92 | -2,473,194.07 |
| 其他收益 | 888,236.42 | 16,241,196.82 | 12,145,650.34 | 10,728,407.28 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 84,803,969.06 | 369,109,991.74 | 316,179,068.63 | 172,434,610.4 |
| 加:营业外收入 | 4,952.11 | 196,084.76 | 354,565.55 | 235,092.35 |
| 减:营业外支出 | 849,500.88 | 4,244,303.61 | 3,009,469.52 | 2,171,589.09 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 83,959,420.29 | 365,061,772.89 | 313,524,164.66 | 170,498,113.66 |
| 减:所得税费用 | 12,408,396.79 | 60,723,377.96 | 51,026,066.64 | 27,875,851.94 |
| 六、净利润 | 71,551,023.5 | 304,338,394.93 | 262,498,098.02 | 142,622,261.72 |
| 持续经营净利润 | 71,551,023.5 | 304,338,394.93 | 262,498,098.02 | 142,622,261.72 |
| 归属于母公司股东的净利润 | 74,342,067.14 | 317,822,381.76 | 272,253,993.52 | 149,230,994.02 |
| 少数股东损益 | -2,791,043.64 | -13,483,986.83 | -9,755,895.5 | -6,608,732.3 |
| (一)基本每股收益 | 0.14 | 0.61 | 0.52 | 0.29 |
| (二)稀释每股收益 | 0.14 | 0.61 | 0.52 | 0.29 |
| 八、其他综合收益 | -998.01 | 6,304.55 | -1,421.66 | 5,375,171.48 |
| 归属于母公司股东的其他综合收益 | -998.01 | 6,304.55 | -1,421.66 | 5,375,171.48 |
| 九、综合收益总额 | 71,550,025.49 | 304,344,699.48 | 262,496,676.36 | 147,997,433.2 |
| 归属于母公司股东的综合收益总额 | 74,341,069.13 | 317,828,686.31 | 272,252,571.86 | 154,606,165.5 |
| 归属于少数股东的综合收益总额 | -2,791,043.64 | -13,483,986.83 | -9,755,895.5 | -6,608,732.3 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-24 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |